Fixed|duration therapy with venetoclax|obinutuzumab in frontline CLL

Venetoclax Plus Obinutuzumab May Improve PFS, Not OS in ...

Among fit patients with previously untreated chronic lymphocytic leukemia (CLL), fixed-duration venetoclax plus obinutuzumab (GV), without ...

Fixed-Duration Therapy for CLL - Patient Power

Two combinations showing promise in treating CLL are ibrutinib-venetoclax and venetoclax-obinutuzumab. The latter was approved by the FDA in May ...

CLL14: feasibility of fixed-duration frontline therapy in CLL - YouTube

Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, shares the long-term results of the Phase III CLL14 study ...

CLL14 - Cancer Trial Results

... Fixed Duration Therapy in Chronic Lymphocytic Leukemia (CLL) in Canada open_in_new. J Clin Oncol 2021 - Minimal Residual Disease Dynamics after Venetoclax ...

Cost-effectiveness of a 12-month fixed-duration venetoclax ...

with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in ... duration VenG in first-line treatment of unfit patients with CLL from a. US ...

First-Line Fixed-Duration Ibrutinib plus Venetoclax Therapy Leads to ...

An important finding of the CAPTIVATE study is that this 1-year fixed-duration regimen of ibrutinib plus venetoclax allows patients a break from ...

Long-Term Data of Venetoclax, Obinutuzumab Fixed-Duration ...

Five-year progression-free survival in the CLL14 trial is approximately 63% in the targeted treatment arm, according to new data.

Novel combination approaches with targeted agents in frontline ...

... fixed-duration therapy with this combination in frontline CLL. ... fixed-duration therapy with obinutuzumab-venetoclax. Along these lines ...

Three-Year Follow-Up Continues to Support Fixed-Dose Venetoclax ...

The FDA approved the venetoclax/obinutuzumab combination as frontline treatment for patients with CLL or small lymphocytic lymphoma in May 2019.

Evolving Role of BTK Inhibitors in the Front-Line Treatment of ...

... fixed-duration combination therapy regimens in CLL,” he added. The CLL14 phase III study corroborated that a time-limited regimen of 6 cycles of obinutuzumab ...

Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients

Source Reference: opens in a new tab or windowHillmen P, et al "Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to ...

Unresolved questions in selection of therapies for treatment-naïve ...

The addition of Ritux and Obi to Ven has facilitated fixed-duration Ven therapy, evolving from continuous Ven therapy first evaluated in R/R CLL ...

Updated Phase 2 CAPTIVATE study results demonstrate sustained ...

... treatment-free periods, with the fixed duration ... obinutuzumab or venetoclax for the treatment of adult patients with previously untreated CLL ...

Frontline CLL Treatment: What's the Right Approach?

Fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: follow-up of efficacy and safety results from ...

First-Line Venetoclax Combination Therapies for CLL - CLL Society

All treatments were limited duration. Chemoimmunotherapy (either fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab) was given for ...

A Probabilistic Cost-Effectiveness Analysis of Venetoclax and ...

A cycle length of 28 days and a time horizon of 10 years was assumed. VEN+O treatment for a fixed duration of 12 months was compared to ...

ESMO Clinical Practice Guideline interim update on new targeted ...

The median duration of treatment with ibrutinib–venetoclax was 27 cycles. A non-powered subgroup analysis of patients with mutated IGHV status ...

CLL & SLL Cancer Treatment | VENCLEXTA® (venetoclax tablets ...

*The VEN+G regimen is designed to be completed after 12 months (twelve 28-day treatment cycles): GAZYVA® (obinutuzumab) is administered in Cycles 1-6, ...

Health‐related quality of life with fixed‐duration venetoclax‐obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from ...

Cost-effectiveness of a 12-month fixed-duration venetoclax ...

CONCLUSIONS: Fixed-duration VenG for 12 months is a cost-effective first-line treatment option for unfit CLL patients compared with other ...